News | June 23, 2026
Teva closes $700M Emalex acquisition
Bolstering neuroscience push with late-stage Tourette therapy
Bolstering neuroscience push with late-stage Tourette therapy
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
She brings extensive expertise in managing global and domestic procurement operations
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
The agreement could rise to $900 million if key commercial milestones are met
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
